JP2022549834A5 - - Google Patents

Info

Publication number
JP2022549834A5
JP2022549834A5 JP2022518780A JP2022518780A JP2022549834A5 JP 2022549834 A5 JP2022549834 A5 JP 2022549834A5 JP 2022518780 A JP2022518780 A JP 2022518780A JP 2022518780 A JP2022518780 A JP 2022518780A JP 2022549834 A5 JP2022549834 A5 JP 2022549834A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022518780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549834A (ja
JP7661315B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/052871 external-priority patent/WO2021062264A1/en
Publication of JP2022549834A publication Critical patent/JP2022549834A/ja
Publication of JP2022549834A5 publication Critical patent/JP2022549834A5/ja
Priority to JP2025061214A priority Critical patent/JP2025111476A/ja
Application granted granted Critical
Publication of JP7661315B2 publication Critical patent/JP7661315B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022518780A 2019-09-25 2020-09-25 高フェニルアラニン血症の治療方法 Active JP7661315B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061214A JP2025111476A (ja) 2019-09-25 2025-04-02 高フェニルアラニン血症の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905720P 2019-09-25 2019-09-25
US62/905,720 2019-09-25
PCT/US2020/052871 WO2021062264A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061214A Division JP2025111476A (ja) 2019-09-25 2025-04-02 高フェニルアラニン血症の治療方法

Publications (3)

Publication Number Publication Date
JP2022549834A JP2022549834A (ja) 2022-11-29
JP2022549834A5 true JP2022549834A5 (cg-RX-API-DMAC7.html) 2023-10-02
JP7661315B2 JP7661315B2 (ja) 2025-04-14

Family

ID=72827023

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022518780A Active JP7661315B2 (ja) 2019-09-25 2020-09-25 高フェニルアラニン血症の治療方法
JP2025061214A Pending JP2025111476A (ja) 2019-09-25 2025-04-02 高フェニルアラニン血症の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061214A Pending JP2025111476A (ja) 2019-09-25 2025-04-02 高フェニルアラニン血症の治療方法

Country Status (23)

Country Link
US (1) US20220362249A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034122B1 (cg-RX-API-DMAC7.html)
JP (2) JP7661315B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220070477A (cg-RX-API-DMAC7.html)
CN (1) CN114650825A (cg-RX-API-DMAC7.html)
AU (1) AU2020353676B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003719A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150003A1 (cg-RX-API-DMAC7.html)
DK (1) DK4034122T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041002T3 (cg-RX-API-DMAC7.html)
FI (1) FI4034122T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251268T1 (cg-RX-API-DMAC7.html)
HU (1) HUE073483T2 (cg-RX-API-DMAC7.html)
IL (1) IL291565B1 (cg-RX-API-DMAC7.html)
JO (1) JOP20220042A1 (cg-RX-API-DMAC7.html)
LT (1) LT4034122T (cg-RX-API-DMAC7.html)
MX (1) MX2022003585A (cg-RX-API-DMAC7.html)
PL (1) PL4034122T3 (cg-RX-API-DMAC7.html)
PT (1) PT4034122T (cg-RX-API-DMAC7.html)
RS (1) RS67295B1 (cg-RX-API-DMAC7.html)
SI (1) SI4034122T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500493T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021062264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) * 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩

Similar Documents

Publication Publication Date Title
EP0209689B1 (en) Use of tetrahydrobiopterins in the preparation of a medicament for the treatment of infantile autism
FI4034122T3 (fi) Menetelmiä hyperfenyylialaninemian hoitamiseksi
US6007824A (en) Natural composition and method for the treatment of sexual dysfunction
US6335021B1 (en) Composition for controlling mood disorders in healthy individuals
JP2024069192A5 (cg-RX-API-DMAC7.html)
JPH05194229A (ja) プテリン誘導体からなる精神疾患症状の治療剤
BE1004168A3 (fr) Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv.
WO2014164285A2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
EP2338495A1 (en) Iron bis-glycinate chelate for use in the oral treatment of anemia in patients with celiac disease
CN102805746A (zh) 一种作用于呼吸系统疾病的复方化学药及其制备工艺与应用
CA2654557A1 (en) Combination preparations comprising bifeprunox and l-dopa
JP2001518481A (ja) 経口投与のためのセロトニン含有製剤及びその使用方法
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤
JPH03170475A (ja) 抑うつ症治療剤
WO2021213502A1 (zh) 包含稀有人参皂苷Rg6和F4的改善睡眠药物组合物
JPH02188523A (ja) 睡眠時無呼吸症治療薬
JP2008535907A5 (cg-RX-API-DMAC7.html)
CN104645334B (zh) N‑乙酰半胱氨酸活性炭组合物及其制备方法和应用
JPH04342528A (ja) アルコール代謝およびアセトアルデヒド代謝促進剤
Obel et al. Potassium supplementation versus bendrofluazide in mildly to moderately hypertensive Kenyans
JPWO2003022290A1 (ja) 糖尿病性神経障害用医薬組成物
TW200940075A (en) Agent for alleviating adverse side effects produced in interferon/ribavirin combination therapy
WO2020207344A1 (zh) 匹莫齐特和甲氨蝶呤的药物组合及其应用
JPS5938204B2 (ja) 再生不良性貧血治療剤
JP2000229853A (ja) 生理痛改善用組成物